ClinicalTrials.gg
CompletedNCT01604278GLOW6Updated Nov 14, 2014Results posted

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of NVA237 50 µg and indacaterol 150 µg and Placebo to NVA237 and indacaterol 150 µg in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals. Completed at 80 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-11-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
23rd of 73
449 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
25th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 23rd largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 25th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Indacaterol
  • Glycopyrronium Bromide
  • COPD
  • bronchodilation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate to severe stable Chronic Obstructive Lung Disease () Stage II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
  • Patients with a post-bronchodilator (FEV1) ≥ 30 % and/or \<80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) \< 0.70 at screening.
  • Current or ex-smokers who have a smoking history of at least 10 pack years
  • Symptomatic patients according to daily diary data.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women.
  • Women of unless using adequate .
  • Patients with Type I or uncontrolled Type II diabetes.
  • Patients with a history of long time interval between start of Q wave and end of T wave in the heart's electrical cycle () syndrome or whose QT corrected for heart rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged
  • Patients with paroxysmal (e.g. intermittent) atrial fibrillation
  • Patients who have a (ECG) or laboratory abnormality at screening (Visit 2)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
449 participants (actual)

Study arms

  • Active comparator
    NVA237 + indacaterol

    Drug: NVA237 50 µg and indacaterol 150 µg

  • Placebo comparator
    Placebo to NVA237 + indacaterol

    Drug: Placebo to NVA237 and indacaterol 150 µg

Interventions

  • DrugNVA237 50 µg and indacaterol 150 µg

    Drug page: Glycopyrrolate

    NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.

    Also known as: Glycopyrronium Bromide

  • DrugPlacebo to NVA237 and indacaterol 150 µg

    Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.

06

What researchers measure

Primary outcomes

  1. Trough Forced Expiratory Volume at 1 Second (FEV1)

    Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

    Time frame: 12 weeks

Secondary outcomes

  1. FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose

    Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

    Time frame: 12 weeks

  2. Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks

    Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

    Time frame: 12 weeks

  3. FEV1 at Individual Time-points

    Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

    Time frame: Day 1, Day 29, Day 57 and Days 84/85

  4. Forced Vital Capacity (FVC) at Individual Time-points

    FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.

    Time frame: Day 1, Day 29, Day 57 and Days 84/85

  5. Inspiratory Capacity (IC) at Individual Time-points

    Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.

    Time frame: Day 1, Days 84/85

  6. Change From Baseline in Mean Daily Number of Puffs of Rescue Medication

    The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.

    Time frame: Baseline, 12 weeks

  7. Transitional Dyspnea Index (TDI) Focal Score

    Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.

    Time frame: baseline, 12 weeks

  8. Change From Baseline in Mean Daily Total and Individual Symptom Scores

    The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).

    Time frame: Baseline, 12 weeks

  9. Number of Participants With Adverse Events and Serious Adverse Events

    All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.

    Time frame: 12 weeks

07

Results

Posted Nov 14, 2014

Participant flow

The number of patients randomized was 449. Of these participants, the Full Analysis Set (FAS) comprised 446 participants who received at least one dose of study drug and had no major deviations which led to removal from the FAS. The Safety Set included 447 participants who received at least one dose of study drug.

Participant flow — Overall Study
MilestoneNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Started226223
Safety set226221
Full analysis set226220
Completed212210
Not completed1413
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up10
Withdrew: Administrative problems21
Withdrew: Withdrawal by subject33
Withdrew: Adverse event35
Withdrew: Protocol deviation53

Outcome measures

PrimaryTrough Forced Expiratory Volume at 1 Second (FEV1)

Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

Time frame:
12 weeks
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume at 1 Second (FEV1)
LitersNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Trough Forced Expiratory Volume at 1 Second (FEV1)1.499 ± 0.01351.436 ± 0.0136
SecondaryFEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose

Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

Time frame:
12 weeks
Reported as:
Least squares mean · Liters
FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose
LitersNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose1.641 ± 0.01321.530 ± 0.0134
SecondaryPeak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks

Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

Time frame:
12 weeks
Reported as:
Least squares mean · Liters
Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks
LitersNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks1.702 ± 0.01371.596 ± 0.0138
SecondaryFEV1 at Individual Time-points

Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.

Time frame:
Day 1, Day 29, Day 57 and Days 84/85
Reported as:
Least squares mean · Liters
FEV1 at Individual Time-points
LitersNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Day 1, 30 minutes (min) post dose (n=208,199)1.544 ± 0.00861.467 ± 0.0088
Day 1, 1 hour (h) post dose (n=214,209)1.589 ± 0.01021.479 ± 0.0104
Day 1, 2 h post dose (n=212,207)1.626 ± 0.01141.506 ± 0.0117
Day 1, 4 h post dose (n=206,213)1.630 ± 0.01221.518 ± 0.0122
Day 1, 23 h 15 min post dose (n=201,203)1.481 ± 0.01181.409 ± 0.0118
Day 1, 23 h 45 min post dose (n=213,204)1.502 ± 0.01091.425 ± 0.0112
Day 29, 45 min pre-dose (n=198,202)1.491 ± 0.01501.438 ± 0.0150
Day 29, 15 min pre-dose (n=198,200)1.524 ± 0.01561.470 ± 0.0155
Day 29, 30 min post dose (n=202,201)1.617 ± 0.01521.508 ± 0.0154
Day 29, 1 h post dose (n=200,199)1.648 ± 0.01441.524 ± 0.0145
Day 56, 45 min pre-dose (n=201,202)1.482 ± 0.01451.418 ± 0.0146
Day 56, 15 min pre-dose (n=199,198)1.509 ± 0.01481.443 ± 0.0149
Day 56, 30 min post dose (n=200,200)1.606 ± 0.01441.495 ± 0.0146
Day 56, 1 h post dose (n=197,204)1.634 ± 0.01491.520 ± 0.0148
Days 84/85, 45 min pre-dose (n=201,206)1.459 ± 0.01271.411 ± 0.0126
Days 84/85, 15 min pre-dose (n=190,196)1.476 ± 0.01291.439 ± 0.0129
Days 84/85, 30 min post dose (n=198,199)1.604 ± 0.01251.514 ± 0.0126
Days 84/85, 1 h post dose (n=201,200)1.638 ± 0.01251.514 ± 0.0126
Days 84/85, 2 h post dose (n=198,201)1.665 ± 0.01391.542 ± 0.0139
Days 84/85, 4 h post dose (n=200,198)1.620 ± 0.01621.529 ± 0.0165
Days 84/85, 23 h 15 min post dose (n=193,188)1.474 ± 0.01391.426 ± 0.0143
Days 84/85, 23 h 45 min post dose (n=197,199)1.508 ± 0.01471.452 ± 0.0148
SecondaryForced Vital Capacity (FVC) at Individual Time-points

FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.

Time frame:
Day 1, Day 29, Day 57 and Days 84/85
Reported as:
Least squares mean · Liters
Forced Vital Capacity (FVC) at Individual Time-points
LitersNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Day 1, 30 min post dose (n=208,199)3.214 ± 0.01813.135 ± 0.0186
Day 1, 1 h post dose (n=214,209)3.295 ± 0.02603.182 ± 0.0264
Day 1, 2 h post dose (n=212,207)3.325 ± 0.02293.200 ± 0.0234
Day 1, 4 h post dose (n=206,213)3.340 ± 0.02393.218 ± 0.0238
Day 1, 23 h 15 min post dose (n=201,203)3.155 ± 0.02673.039 ± 0.0268
Day 1, 23 h 45 min post dose (n=213,204)3.201 ± 0.02573.095 ± 0.0263
Day 29, 45 min pre-dose (n=198,202)3.146 ± 0.02993.043 ± 0.0299
Day 29, 15 min pre-dose (n=198,200)3.184 ± 0.03153.092 ± 0.0314
Day 29, 30 min post dose (n=202,201)3.316 ± 0.03383.201 ± 0.0341
Day 29, 1 h post dose (n=200,199)3.362 ± 0.03363.197 ± 0.0337
Day 56, 45 min pre-dose (n=201,202)3.102 ± 0.03023.015 ± 0.0303
Day 56, 15 min pre-dose (n=199,198)3.156 ± 0.03213.086 ± 0.0322
Day 56, 30 min post dose (n=200,200)3.282 ± 0.03163.190 ± 0.0319
Day 56, 1 h post dose (n=197,204)3.327 ± 0.03233.219 ± 0.0321
Days 84/85, 45 min pre-dose (n=201,206)3.052 ± 0.02803.016 ± 0.0279
Days 84/85, 15 min pre-dose (n=190,196)3.064 ± 0.02563.012 ± 0.0254
Days 84/85, 30 min post dose (n=198,199)3.246 ± 0.02623.162 ± 0.0264
Days 84/85, 1 h post dose (n=201,200)3.312 ± 0.02913.179 ± 0.0294
Days 84/85, 2 h post dose (n=198,201)3.318 ± 0.02613.181 ± 0.0261
Days 84/85, 4 h post dose (n=200,198)3.251 ± 0.02923.161 ± 0.0297
Days 84/85, 23 h 15 min post dose (n=193,188)3.123 ± 0.02853.050 ± 0.0292
Days 84/85, 23 h 45 min post dose (n=197,199)3.136 ± 0.02563.047 ± 0.0258
SecondaryInspiratory Capacity (IC) at Individual Time-points

Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.

Time frame:
Day 1, Days 84/85
Reported as:
Least squares mean · Liters
Inspiratory Capacity (IC) at Individual Time-points
LitersNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Day 1, 25 min post dose (n=164,168)2.493 ± 0.02342.434 ± 0.0231
Day 1, 1 h 55 min (n=161,176)2.587 ± 0.02942.478 ± 0.0287
Day 1, 3 h 55 min (n=160,173)2.557 ± 0.02982.475 ± 0.0291
Days 84/85, 20 min pre-dose (n=144,148)2.444 ± 0.03272.363 ± 0.0324
Days 84/85, 25 min post dose (n=149,145)2.580 ± 0.03722.420 ± 0.0377
Days 84/85, 1 h 55 min post dose (n=146,153)2.607 ± 0.03882.485 ± 0.0384
Days 84/85, 3 h 55 min (n=146,145)2.577 ± 0.03322.439 ± 0.0333
Days 84/85, 23 h 40 min (n=153,150)2.405 ± 0.03712.337 ± 0.0376
SecondaryChange From Baseline in Mean Daily Number of Puffs of Rescue Medication

The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Number of puffs
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
Number of puffsNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication-1.9 ± 0.16-1.8 ± 0.16
SecondaryTransitional Dyspnea Index (TDI) Focal Score

Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · Score
Transitional Dyspnea Index (TDI) Focal Score
ScoreNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Transitional Dyspnea Index (TDI) Focal Score2.506 ± 0.27812.012 ± 0.2797
SecondaryChange From Baseline in Mean Daily Total and Individual Symptom Scores

The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · Score
Change From Baseline in Mean Daily Total and Individual Symptom Scores
ScoreNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Total symptom score-1.2 ± 0.13-1.1 ± 0.13
Respiratory symptom score-0.3 ± 0.03-0.2 ± 0.03
Cough symptom score-0.2 ± 0.03-0.2 ± 0.03
Wheeze symptom score-0.3 ± 0.03-0.2 ± 0.03
Sputum production score-0.1 ± 0.03-0.1 ± 0.03
Sputum color score-0.1 ± 0.02-0.1 ± 0.02
Breathless symptom score-0.2 ± 0.03-0.2 ± 0.03
Sore throat symptom score0.0 ± 0.010.0 ± 0.01
Cold symptom score0.0 ± 0.020.0 ± 0.02
Fever symptom score0.0 ± 0.010.0 ± 0.01
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events

All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.

Time frame:
12 weeks
Reported as:
Number · Number of participants
Number of Participants With Adverse Events and Serious Adverse Events
Number of participantsNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Adverse Events (serious and non-serious)8575
Serious adverse events55
Deaths00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 + Indacaterol—5/226 (2.2%)32/226 (14.2%)
Placebo to NVA237 + Indacaterol—5/221 (2.3%)27/221 (12.2%)
Most frequent serious events
Most frequent serious events
EventNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/2262/221
Angina pectorisCardiac disorders0/2261/221
Urinary tract infectionInfections and infestations0/2261/221
Rib fractureInjury, poisoning and procedural complications0/2261/221
Renal failure acuteRenal and urinary disorders0/2261/221
Inguinal herniaGastrointestinal disorders1/2260/221
HypersensitivityImmune system disorders1/2260/221
Bacterial infectionInfections and infestations1/2260/221
OsteitisMusculoskeletal and connective tissue disorders1/2260/221
HaemoptysisRespiratory, thoracic and mediastinal disorders1/2260/221
Most frequent other events
Most frequent other events
EventNVA237 + IndacaterolPlacebo to NVA237 + Indacaterol
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders32/22627/221

Baseline characteristics

The baseline characteristics table was based on the safety set.

Age, Continuous
Age, Continuous(Years)NVA237 + IndacaterolPlacebo to NVA237 + IndacaterolTotal
Mean63.4 ± 8.4464.1 ± 7.6763.7 ± 8.07
Sex: Female, Male
Sex: Female, Male(Participants)NVA237 + IndacaterolPlacebo to NVA237 + IndacaterolTotal
Female463581
Male180186366
08

Study locations

80 sites
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Genk, 3600, Belgium
  • Novartis Investigative Site
    Gilly, 6060, Belgium
  • Novartis Investigative Site
    Gosselies, 6041, Belgium
  • Novartis Investigative Site
    Hasselt, 3500, Belgium
  • Novartis Investigative Site
    Herentals, 2200, Belgium
  • Novartis Investigative Site
    Jambes, 5100, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Luxembourg, 1210, Belgium
  • Novartis Investigative Site
    Malmedy/Bellevaux-Ligneuville, 4960, Belgium
  • Novartis Investigative Site
    Montigny-le-tilleul, 6110, Belgium
  • Novartis Investigative Site
    Turnhout, 2300, Belgium
  • Novartis Investigative Site
    Yvoir, 5530, Belgium
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Ruse, 7002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1000, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, 6000, Bulgaria
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Athens, GR 106 76, Greece
  • Novartis Investigative Site
    Athens, GR 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 564 03, Greece
  • Novartis Investigative Site
    Athens, 11527, Greece
  • Novartis Investigative Site
    Budapest, 1046, Hungary
  • Novartis Investigative Site
    Budapest, 1121, Hungary
  • Novartis Investigative Site
    Deszk, 6772, Hungary
  • Novartis Investigative Site
    Erd, H-2030, Hungary
  • Novartis Investigative Site
    Godollo, 2100, Hungary
  • Novartis Investigative Site
    Wilton, Cork, Ireland
  • Novartis Investigative Site
    Moscow, 125315, Russian Federation
  • Novartis Investigative Site
    N.Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Nizhny Novgorod, 603018, Russian Federation
  • Novartis Investigative Site
    Saratov, 410012, Russian Federation
  • Novartis Investigative Site
    Bardejov, Slovak Republic 085 01, Slovakia
  • Novartis Investigative Site
    Bojnice, Slovak Republic 972 01, Slovakia
  • Novartis Investigative Site
    Liptovsky Hradok, Slovak Republic 033 01, Slovakia
  • Novartis Investigative Site
    Námestovo, Slovensko 02901, Slovakia
  • Novartis Investigative Site
    Bratislava, 826 06, Slovakia
  • Novartis Investigative Site
    Kosice, 040 01, Slovakia
  • Novartis Investigative Site
    Kralovsky Chlmec, 077 01, Slovakia
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Gijon, Asturias 33290, Spain
  • Novartis Investigative Site
    Torrelavega, Cantabria 39300, Spain
  • Novartis Investigative Site
    Illescas, Castilla la Mancha 45200, Spain
  • Novartis Investigative Site
    Ponferrada, Castilla y Leon 24400, Spain
  • Novartis Investigative Site
    Centelles, Cataluña 08540, Spain
  • Novartis Investigative Site
    Salt, Cataluña 17190, Spain
  • Novartis Investigative Site
    Sant Boi de Llobregat, Cataluña 08830, Spain
  • Novartis Investigative Site
    Viladecans, Cataluña, Spain
  • Novartis Investigative Site
    Mérida, Extremadura 06800, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Ankara, 06490, Turkey
  • Novartis Investigative Site
    Istanbul, 34854, Turkey
  • Novartis Investigative Site
    Istanbul, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
  • Novartis Investigative Site
    Mersin, 33079, Turkey
  • Novartis Investigative Site
    Yenisehir/Izmir, 35110, Turkey
  • Novartis Investigative Site
    Burnhope, County Durham DH7 0BD, United Kingdom
  • Novartis Investigative Site
    Alderton, Suffolk IP12 3DA, United Kingdom
  • Novartis Investigative Site
    Atherstone, Warwickshire CV9 1EU, United Kingdom
  • Novartis Investigative Site
    Leamington Spa, Warwickshire CV32 4RA, United Kingdom
  • Novartis Investigative Site
    Strensall, Yorkshire YO32 5UA, United Kingdom
  • Novartis Investigative Site
    Bath, BA1 2SR, United Kingdom
  • Novartis Investigative Site
    Bexhill-on-Sea, TN40 1JJ, United Kingdom
  • Novartis Investigative Site
    Blackpool, FY3 7EN, United Kingdom
  • Novartis Investigative Site
    Bradford, BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB7 5JD, United Kingdom
  • Novartis Investigative Site
    Chesterfield, S40 4AA, United Kingdom
  • Novartis Investigative Site
    Huntingdon, PE29 6NT, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 2RN, United Kingdom
  • Novartis Investigative Site
    Newcastle-upon-Tyne, NE7 7DN, United Kingdom
  • Novartis Investigative Site
    Newton Aycliffe, DL5 4SE, United Kingdom
  • Novartis Investigative Site
    Reading, RG7 3SQ, United Kingdom
  • Novartis Investigative Site
    Southbourne, United Kingdom
  • Novartis Investigative Site
    Telford, TF1 6TF, United Kingdom
  • Novartis Investigative Site
    Watford, WD25 0EA, United Kingdom
  • Novartis Investigative Site
    Wiltshire, SN15 2SB, United Kingdom
09

References and documents

Publications

  • Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:215-28. doi: 10.2147/COPD.S51592. eCollection 2014. PubMed 24596459 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2012
First posted
May 23, 2012
Start
May 2012
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Nov 14, 2014
Last update
Nov 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01604278
Responsible party
Sponsor
First posted
May 23, 2012
Start date
May 2012
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Nov 14, 2014
Last update
Nov 14, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion